Showing 2001-2010 of 5771 results for "".
- Topcon Announces the European Launch of Chronoshttps://modernod.com/news/topcon-announces-the-european-launch-of-chronos/2478579/Topcon Healthcare announced the European launch of the Chronos Automated Binocular Refraction System with SightPilot guided refraction software. Topcon Chronos is a complete digital refraction solution that combines autorefraction, keratometry, and subjective refraction in a single device.
- Topcon Announces Launch of Chronos Binocular Refraction Systemhttps://modernod.com/news/topcon-announces-the-us-launch-of-chronos/2478562/Topcon Healthcare announced that it has launched the Chronos Automated Binocular Refraction System with SightPilot guided refraction software. Topcon Chronos is a digital refraction solution that combines autorefraction, keratometry, and subjective refraction in a single device that occupi
- Innovent Announces the Results of the Phase 1 Clinical Trial of IBI302 for Wet AMD at AAO 2020https://modernod.com/news/innovent-announces-the-results-of-the-phase-1-clinical-trial-of-ibi302-for-wet-amd-at-aao-2020/2478560/Innovent Biologics announces that the results of the phase 1 clinical trial of IBI302, a first-in-class ophthalmic recombinant human anti-VEGF and anti-complement bi-specific fusion protein for wet age-related macular degeneration (AMD) is released in e-poster at 2020 American Academy of Ophthalm
- Adverum Biotechnologies Announces Positive Interim Data From OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-positive-interim-data-from-optic-phase-1-trial-of-advm-022-intravitreal-gene-therapy-for-wet-amd/2478553/Adverum Biotechnologies announced positive new interim data from Cohorts 1-4 of the OPTIC phase 1 clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). “With these impre
- Clearside Biomedical Announces Data Presentations at the AAO 2020https://modernod.com/news/clearside-biomedical-announces-data-presentations-at-the-aao-2020/2478556/Clearside Biomedical announced that two presentations of Clearside preclinical and clinical data were given at the virtual American Academy Ophthalmology (AAO) 2020 Annual Meeting. Clearside also announced a clinical characterization of the suprachoroidal in
- Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at AAO Virtualhttps://modernod.com/news/oyster-point-pharma-announces-clinical-data-presentations-on-oc-01-nasal-spray-for-dry-eye-disease-at-aao-virtual/2478548/Oyster Point Pharma announced new data from its phase 2 IMPERIAL clinical trial evaluating OC-01 (varenicline) nasal spray in the treatment of the signs and symptoms of dry eye disease in adults at the AAO 2020 Virtual Annual Meeting, being held on November 13-15. A single administration o
- Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy at AAO 2020 Virtualhttps://modernod.com/news/apellis-announces-late-breaking-presentation-of-largest-retrospective-database-study-in-geographic-atrophy-at-aao-2020-virtual/2478547/Apellis Pharmaceuticals announced findings from a large retrospective database study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analysis of the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry was conducted in partnership wit
- Gemini Therapeutics Announces GEM103 Meets All Endpoints in Phase 1 Clinical Studyhttps://modernod.com/news/gemini-therapeutics-announces-gem103-meets-all-endpoints-in-phase-1-clinical-study/2478546/Gemini Therapeutics announced that the phase 1 study of GEM103, the company’s investigational treatment for dry AMD, met all its endpoints. Results demonstrate that in 12 patients receiving a single intravitreal (IVT) injection of GEM103, there were no dose-limiting toxicities or treatment-
- Nanoscope Therapeutics Announces Presentation at the 2020 AAOhttps://modernod.com/news/nanoscope-therapeutics-announces-presentation-at-the-2020-aao/2478545/Nanoscope Therapeutics, which is developing ocular gene therapy based on its proprietary ambient light activatable MCO Optogenetic Technology Platform, announced that an oral presentation at the Late Breaking Developments session of Retina Subspecialty Day will be made during the American Academy
- Adaptilens Announces $1.6 Million in Seed Funding for Development of Accommodating IOLhttps://modernod.com/news/adaptilens-announces-1-6-million-in-seed-funding-for-development-of-accommodating-iol/2478536/Adaptilens announced a $1.6 million seed funding to fund the company’s development of an innovative accommodating IOL with the aim of allowing patients to live their lives free of glasses and contact lenses. The funding was led by Pillar VC with additional participat